You need JavaScript to view this

Diagnosis and treatment of leukemia recognized in atomic-bomb survivors

Journal Article:

Abstract

Out of atomic bomb survivors in Hiroshima and Nagasaki, 256 patients which were diagnosed as having leukemia by 1975 and of which exposure dose was estimated as over 1 rad were described. Chronic myelocytic leukemia (CGL) was plentiful in Hiroshima, and acute myelocytic leukemia (AGL) was comparatively plentiful in Nagasaki. Chronic lymphatic leukemia (CLL) was not recognized in the atomic bomb survivors exposed at places near the center of the explosion, but CLL was recognized plentifully in the atomic bomb survivors exposed to radiation of under 1 rad. The incidence of leukemia according to the total dose was higher in Hiroshima than in Nagasaki. When RBE of neutron on the occurrence of leukemia was considered to be five times that of gamma-ray, the occurrence curves in both cities were consistent well. As to a relationship between leukemia in the atomic bomb survivors and the age at the exposure time, CGL occurred early in the atomic bomb survivors exposed at an early age. A specific lesion of leukemia in the atomic bomb survivors was not recognized, but cases of which leukemia cells were negative to peroxidase and were very difficult to be identified were plentiful in the atomic bomb survivors exposed  More>>
Authors:
Ichimaru, M [1] 
  1. Nagasaki Univ. (Japan). School of Medicine
Publication Date:
May 01, 1978
Product Type:
Journal Article
Reference Number:
AIX-10-430066; EDB-79-113583
Resource Relation:
Journal Name: Rinsho To Kenkyu; (Japan); Journal Volume: 55:5
Subject:
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.; A-BOMB SURVIVORS; LEUKEMOGENESIS; AGE DEPENDENCE; DELAYED RADIATION EFFECTS; DOSE-RESPONSE RELATIONSHIPS; HIROSHIMA; MEDICAL SURVEILLANCE; MYELOID LEUKEMIA; NAGASAKI; RADIATION DOSES; ASIA; BIOLOGICAL EFFECTS; BIOLOGICAL RADIATION EFFECTS; CARCINOGENESIS; DISEASES; DOSES; HEMIC DISEASES; JAPAN; LEUKEMIA; NEOPLASMS; PATHOGENESIS; RADIATION EFFECTS; 560151* - Radiation Effects on Animals- Man
OSTI ID:
5932231
Country of Origin:
Japan
Language:
Japanese
Other Identifying Numbers:
Journal ID: CODEN: RIKEA
Submitting Site:
INIS
Size:
Pages: 1519-1526
Announcement Date:

Journal Article:

Citation Formats

Ichimaru, M. Diagnosis and treatment of leukemia recognized in atomic-bomb survivors. Japan: N. p., 1978. Web.
Ichimaru, M. Diagnosis and treatment of leukemia recognized in atomic-bomb survivors. Japan.
Ichimaru, M. 1978. "Diagnosis and treatment of leukemia recognized in atomic-bomb survivors." Japan.
@misc{etde_5932231,
title = {Diagnosis and treatment of leukemia recognized in atomic-bomb survivors}
author = {Ichimaru, M}
abstractNote = {Out of atomic bomb survivors in Hiroshima and Nagasaki, 256 patients which were diagnosed as having leukemia by 1975 and of which exposure dose was estimated as over 1 rad were described. Chronic myelocytic leukemia (CGL) was plentiful in Hiroshima, and acute myelocytic leukemia (AGL) was comparatively plentiful in Nagasaki. Chronic lymphatic leukemia (CLL) was not recognized in the atomic bomb survivors exposed at places near the center of the explosion, but CLL was recognized plentifully in the atomic bomb survivors exposed to radiation of under 1 rad. The incidence of leukemia according to the total dose was higher in Hiroshima than in Nagasaki. When RBE of neutron on the occurrence of leukemia was considered to be five times that of gamma-ray, the occurrence curves in both cities were consistent well. As to a relationship between leukemia in the atomic bomb survivors and the age at the exposure time, CGL occurred early in the atomic bomb survivors exposed at an early age. A specific lesion of leukemia in the atomic bomb survivors was not recognized, but cases of which leukemia cells were negative to peroxidase and were very difficult to be identified were plentiful in the atomic bomb survivors exposed within 2 km from the explosion center. The treatment of leukemia in atomic bomb survivors does not differ from that of general leukemia, but a method of treatment, administration dosage, a method and a kind of supportive care must be discussed according to each case.}
journal = {Rinsho To Kenkyu; (Japan)}
volume = {55:5}
journal type = {AC}
place = {Japan}
year = {1978}
month = {May}
}